Back to top
more

Immatics (IMTX)

(Real Time Quote from BATS)

$9.38 USD

9.38
183,860

+0.03 (0.32%)

Updated Nov 5, 2024 03:38 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value B Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (94 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Immatics (IMTX) Moves 23.2% Higher: Will This Strength Last?

by Zacks Equity Research

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Down -19.29% in 4 Weeks, Here's Why You Should You Buy the Dip in Immatics (IMTX)

by Zacks Equity Research

Immatics (IMTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Moderna (MRNA), Immatics Ink Deal to Develop New Cancer Therapies

by Zacks Equity Research

The deal will combine Moderna (MRNA) and Immatics' (IMTX) proprietary platforms to develop innovative immunotherapies for cancer.

How Much Upside is Left in Immatics (IMTX)? Wall Street Analysts Think 45.78%

by Zacks Equity Research

The consensus price target hints at a 45.8% upside potential for Immatics (IMTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Immatics (IMTX) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Immatics (IMTX) delivered earnings and revenue surprises of -2.94% and 28.28%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) Surges 7.5%: Is This an Indication of Further Gains?

by Zacks Equity Research

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ProQR (PRQR) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

ProQR (PRQR) delivered earnings and revenue surprises of 0% and 75.51%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

Absci Corporation (ABSI) delivered earnings and revenue surprises of -8.33% and 41.44%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

PhenomeX Inc. (CELL) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

PhenomeX Inc. (CELL) delivered earnings and revenue surprises of -11.11% and 3.52%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia Pharmaceuticals (ACAD) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Acadia (ACAD) delivered earnings and revenue surprises of -28.57% and 2.66%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NGM Biopharmaceuticals (NGM) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

NGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of -11.54% and 67.55%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Immatics (IMTX) Moves 27.5% Higher: Will This Strength Last?

by Zacks Equity Research

Immatics (IMTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Immatics (IMTX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Immatics (IMTX) delivered earnings and revenue surprises of -3.23% and 13.62%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Ginkgo Bioworks Holdings, Inc. (DNA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Ginkgo Bioworks Holdings, Inc. (DNA) delivered earnings and revenue surprises of -60% and 22.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -3.13% and 15.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Vericel Corporation (VCEL) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

Vericel Corporation (VCEL) delivered earnings and revenue surprises of -16.67% and 3.68%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Does Immatics (IMTX) Have the Potential to Rally 77% as Wall Street Analysts Expect?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 76.9% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts See an 81% Upside in Immatics (IMTX): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Immatics (IMTX) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Immatics (IMTX) Moves 11.6% Higher: Will This Strength Last?

by Zacks Equity Research

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Wall Street Analysts Think Immatics (IMTX) Could Surge 82%: Read This Before Placing a Bet

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 81.5% in Immatics (IMTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Immatics (IMTX) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Immatics (IMTX) delivered earnings and revenue surprises of -276.92% and 56.96%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Voyager Therapeutics (VYGR) delivered earnings and revenue surprises of 10.71% and 71.52%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Immatics (IMTX): Can Its 18% Jump Turn into More Strength?

by Zacks Equity Research

Immatics (IMTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Immatics (IMTX) Stock Jumps 5.2%: Will It Continue to Soar?

by Zacks Equity Research

Immatics (IMTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

BMY, IMTX Extend Deal to Develop Cell Therapies for Cancer

by Zacks Equity Research

Bristol Myers (BMY) strengthens its partnership with the small biotech company Immatics (IMTX) to develop multiple allogenic cell therapies targeting multiple cancer indications.